                         SEQUENCE LISTING

<110>  ADC THERAPEUTICS SA
       MEDIMMUNE LIMITED
       SABLINSKI, Tomasz
 
<120>  Treatment of Car T-Cell Toxicity

<130>  RKA/LP7438708

<150>  GB 1802172.5
<151>  2018-02-09

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  127
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  AB12 VH

<400>  1

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 
1               5                   10                  15      


Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Arg Tyr 
            20                  25                  30          


Ile Ile Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 
        35                  40                  45              


Gly Arg Ile Ile Pro Ile Leu Gly Val Glu Asn Tyr Ala Gln Lys Phe 
    50                  55                  60                  


Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Lys Asp Trp Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr 
            100                 105                 110         


Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala 
        115                 120                 125         


<210>  2
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  AB12 VL

<400>  2

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 
            100                 105                 110         


Pro Ser Val Phe Ile Phe Pro 
        115                 


<210>  3
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH CDR1

<400>  3

Arg Tyr Ile Ile Asn 
1               5   


<210>  4
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH CDR2

<400>  4

Arg Ile Ile Pro Ile Leu Gly Val Glu Asn Tyr Ala Gln Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  5
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH CDR3

<400>  5

Lys Asp Trp Phe Asp Tyr 
1               5       


<210>  6
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR1

<400>  6

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR2

<400>  7

Gly Ala Ser Ser Arg Ala Thr 
1               5           


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL CDR3

<400>  8

Gln Gln Tyr Gly Ser Ser Pro Leu Thr 
1               5                   


